Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 98 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lumpectomy/Mastectomy Clear all
Active, not recruiting Phase 2 Interventional

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

NCT04266249
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine
Drug · Procedure · Biological + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
2,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
999
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 10, 2026, 1:43 PM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy

NCT02610621
View directory record Official record
Conditions
Breast Cancer
Interventions
Lumpectomy without sentinel node biopsy
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 10, 2026, 1:43 PM EDT
Completed Phase 1 Interventional

Pre-Operative Radiation and Veliparib for Breast Cancer

NCT01618357
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation, Lumpectomy/Mastectomy, Veliparib
Radiation · Procedure · Drug
Lead sponsor
Richard Zellars
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
6
States / cities
Avon, Indiana • Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 10, 2026, 1:43 PM EDT
Terminated Not applicable Interventional Results available

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

NCT01409811
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
zoledronic acid, laboratory biomarker analysis, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 10, 2026, 1:43 PM EDT
Not listed Phase 3 Interventional Results available

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

NCT00408408
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, capecitabine, cyclophosphamide, docetaxel, doxorubicin hydrochloride (Adriamycin), gemcitabine hydrochloride
Biological · Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
1,206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
432
States / cities
Little Rock, Arkansas • Castro Valley, California • Fremont, California + 287 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 10, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer

NCT00005800
View directory record Official record
Conditions
Breast Cancer
Interventions
Filgrastim, Docetaxel, Doxorubicin, Surgery
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Sep 10, 2026, 1:43 PM EDT
Completed Phase 1Phase 2 Interventional

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

NCT05900986
View directory record Official record
Conditions
Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
Interventions
LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg, LS301-IT 0.1 mg/kg
Drug
Lead sponsor
Integro Theranostics
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Weston, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 10, 2026, 1:43 PM EDT
Terminated Not applicable Interventional

Isoflavones in Treating Women Who Have Breast Cancer and Are Planning to Undergo Mastectomy or Lumpectomy

NCT00036686
View directory record Official record
Conditions
Breast Cancer
Interventions
Soy protein isolate, Placebo
Dietary Supplement · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
7
States / cities
Phoenix, Arizona • Tampa, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2012 · Synced Sep 10, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional

Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer

NCT00080626
View directory record Official record
Conditions
Breast Cancer
Interventions
pegfilgrastim, docetaxel, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Sep 10, 2026, 1:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

NCT00574587
View directory record Official record
Conditions
Breast Cancer
Interventions
Vorinostat, Paclitaxel, Trastuzumab, Doxorubicin, Cyclophosphamide, Surgery
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 10, 2026, 1:43 PM EDT
Terminated Early Phase 1 Interventional

Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

NCT00651976
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole, Blood Collection, biopsy/lumpectomy/mastectomy
Drug · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
5
States / cities
Atlanta, Georgia • Tulsa, Oklahoma • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 10, 2026, 1:43 PM EDT
Recruiting Not applicable Interventional

Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma

NCT03909282
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ
Interventions
Lumpectomy, Partial breast irradiation prior to surgery
Procedure · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 10, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

NCT00003992
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
44
States / cities
Palo Alto, California • Stanford, California • Denver, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 10, 2026, 1:43 PM EDT
Active, not recruiting Not applicable Interventional

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

NCT01872975
View directory record Official record
Conditions
Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
regional nodal XRT, chestwall XRT, WBI
Radiation
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
1,636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
489
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 356 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 10, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional Results available

Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery

NCT01234532
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Triple-negative Breast Cancer
Interventions
entinostat, anastrozole, diagnostic laboratory biomarker analysis, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 10, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer

NCT00675259
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, carboplatin, nab-paclitaxel, Surgery, Adjuvant chemotherapy
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 10, 2026, 1:43 PM EDT
Completed No phase listed Observational Results available

Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation

NCT02348684
View directory record Official record
Conditions
Node Positive Breast Cancer
Interventions
Radiation therapy groups
Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 95 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 10, 2026, 1:43 PM EDT
Recruiting Not applicable Interventional

Cryoablation vs Lumpectomy in T1 Breast Cancers

NCT05505643
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm
Interventions
Endocare SlimLine Cryoprobe, Lumpectomy
Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 10, 2026, 1:43 PM EDT
Active, not recruiting Not applicable Interventional

Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer

NCT02400658
View directory record Official record
Conditions
Breast Cancer
Interventions
IORT with CT-Guided HDR Brachytherapy
Device
Lead sponsor
Shayna Showalter, MD
Other
Eligibility
45 Years and older · Female only
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
3
States / cities
Hackensack, New Jersey • Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 10, 2026, 1:43 PM EDT
Withdrawn No phase listed Observational

Post-Breast Procedure Pain Syndrome Study

NCT01114984
View directory record Official record
Conditions
Breast, Mastectomy, Segmental
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2015 · Synced Sep 10, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional

Shave Margins in Breast Conservation Therapy

NCT02462200
View directory record Official record
Conditions
Breast Cancer, Cancer of Breast, Cancer of the Breast
Interventions
Breast-conserving surgery (BCS), Cavity shave margins (CSM), BREAST-Q Questionnaire, 3-D breast imaging, Indocyanine green, Intraoperative imaging device, Peripheral blood draw
Procedure · Behavioral · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Sep 10, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery

NCT00749931
View directory record Official record
Conditions
Breast Cancer
Interventions
MarginProbe, Lumpectomy
Device · Procedure
Lead sponsor
Dune Medical Devices
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
18
States / cities
Costa Mesa, California • Los Angeles, California • Newport Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 10, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

NCT00944047
View directory record Official record
Conditions
Breast Cancer
Interventions
nab-paclitaxel, trastuzumab, Doxorubicin, cyclophosphamide, Growth Factor Support, Surgery
Drug · Biological · Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Hays, Kansas • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Sep 10, 2026, 1:43 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

NCT00726180
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab (Herceptin®)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Sep 10, 2026, 1:43 PM EDT